106 results about "Intestinal juice" patented technology

The invention relates to the technical field of microorganisms, in particular to bifidobacterium bifidum BGLP1 capable of regulating sugar digestion and producing GLP-1 at high yield and application of the bifidobacterium bifidum BGLP1. The preservation number of the bifidobacterium bifidum BGLP1 is CGMCC (China General Microbiological Culture Collection Center) No.35718, and the bifidobacterium bifidum BGLP1 can be used for preparing the feed additive. The strain has the capability of inhibiting alpha-glucosidase and alpha-amylase; sTC-1 cells are stimulated to secrete GLP-1, and the blood glucose reducing pathway capacity of the intestinal tract is activated; the activity of pancreatic lipase is obviously inhibited, and the dietary fat absorption capability can be effectively reduced; redundant cane sugar is converted into exopolysaccharide, so that the probiotic function capability is improved; the capability of converting white fat into brown fat is promoted; macrophages are activated, and the body immune function is improved. In addition, the bifidobacterium bifidum BGLP1 also has relatively strong intestinal colonization ability, has good tolerance in artificial gastric juice and artificial intestinal juice, and can smoothly reach the intestinal tract of a human body.

The invention relates to the technical field of medical instruments, in particular to a negative pressure flushing type rectal anastomotic fistula treatment device with a blocking balloon, which comprises a drainage tube, a balloon, an annular sponge sleeve, a water injection tube and a filling tube, the balloon is arranged at the near end of the drainage tube, and the filling tube is communicated with the balloon and used for filling media into the balloon to block an enteric cavity; the annular sponge sleeve wraps the outer side of the drainage tube below the balloon, and a side hole II is formed in the section, wrapped by the annular sponge sleeve, of the drainage tube; the water injection pipe is arranged on the drainage pipe and used for injecting flushing fluid into the annular sponge sleeve area. The far end of the drainage tube is used for being connected with a negative pressure device so that a continuous negative pressure drainage environment can be formed in the annular sponge sleeve area, the negative pressure flushing type rectum anastomotic fistula treatment device with the blocking balloon does not need to be placed under an endoscope and only needs to be placed under direct vision of an anoscope, and operation is easy; near-end intestinal juice can be blocked, and the influence of the intestinal juice on healing of an anastomotic stoma is reduced.

The invention provides a pet hair decomposer with synergistic effect of bacillus subtilis and keratinase, the pet hair decomposer comprises bacillus subtilis ZYpet-015 and keratinase, the preservation number of the bacillus subtilis ZYpet-015 is CGMCC (China General Microbiological Culture Collection Center) No.34790, and the preservation date is June 6, 2025; the protease activity of the bacillus subtilis is greater than or equal to 129.92 U, the survival rate of the bacillus subtilis in simulated gastric juice within 3 hours is greater than 50%, and the tolerance rate of the bacillus subtilis in intestinal juice within 4 hours is greater than 90%. According to the pet hair decomposing agent, hair keratin is synergistically degraded through protease secreted by the bacillus subtilis ZYpet-015 and keratinase, and the hair decomposing efficiency reaches 28.07% + / -2.79% and is remarkably higher than that of a single treatment group. Meanwhile, experiments prove that the pet hair decomposer can effectively destroy the hair cuticle structure, is suitable for a pet hair-melting nutritional supplement and can relieve the hair ball symptom.

The invention relates to the field of medical apparatus and instruments in rectum surgery, and particularly provides a novel multifunctional intestinal bypass device for rectum surgery, which comprises a hollow sleeve, a film sleeve, a decompression air bag sleeved outside the hollow sleeve, and an inflation channel, wherein after being inflated, the decompression air bag protrudes in a corrugated or threaded mode in the axial direction of the hollow sleeve, the protruding part makes contact with the intestinal wall to provide friction force, and a decompression gap is formed between the sunken part and the intestinal wall; according to the invention, intestinal contents are discharged from the hollow sleeve and the film sleeve, so that excrement or intestinal juice is prevented from being in contact with an anastomotic stoma, the infection risk of the anastomotic stoma is reduced, and the healing rate of the anastomotic stoma is accelerated; the thin film sleeve is soft and deformable, so that discomfort such as anus falling expansion, pain and tenesmus of a patient can be effectively reduced, and the comfort of the patient is improved; the decompression air bag is expanded through the inflation channel, the hollow sleeve is positioned, meanwhile, blood supply of the intestinal wall is protected, and the reliable effect of replacing preventive fistulization is achieved.

The application discloses application of white ginseng mushroom in preparation of a medicine for treating hyperuricemia, and belongs to the technical field of deep processing of edible mushrooms. The white ginseng mushroom is vacuum freeze-dried, ground into powder, other traditional Chinese medicine ingredients are extracted, concentrated, and spray-dried into powder; the white ginseng mushroom powder is mixed with sodium carboxymethyl cellulose and guar gum solution to form a mushroom suspension colloid, the microcapsules are collected after being dropped into a calcium-containing aqueous solution; the microcapsules are immersed in a high polymer compound solution for treatment, finally mixed with a stabilizer paste, and then filled after being treated by a high-pressure homogenizer and sterilized. Compared with the prior art, the medicine has good stability in simulated gastric juice, can be quickly released in simulated intestinal juice, significantly improves the bioavailability and curative effect of the medicine, can effectively reduce the serum uric acid level, improve liver and kidney functions, and regulate the intestinal flora structure, and has a significant uric acid-lowering effect and multi-target synergistic effect.

This application relates to the field of functional composition technology, and in particular to a GABA-vitamin D neuroprotective composition and its preparation method, comprising medium-chain triglycerides, modified phospholipids, and a GABA-vitamin D blend. This application utilizes the low interfacial tension and strong amphiphilic compatibility of medium-chain triglycerides and modified phospholipids, enabling them to be miscible with the blend, thus improving the characteristics of GABA and vitamin D being easily degraded and oxidatively inactivated under complex physiological environments, and solving the problems of poor stability and asynchronous absorption. In the preparation method, the preferred component mass ratio is (0.6–1.5):1:(1–1.6), and mixing is carried out at 50–80°C for 10–60 min. The resulting system features high encapsulation efficiency, uniform particle size distribution, and high bioavailability. After treatment in simulated gastric fluid (pH 1.2) for 2 hours, the average GABA retention rate is ≥88% (optimal up to 94.3%), and the average vitamin D retention rate is ≥94% (optimal up to 96.8%). After treatment in simulated intestinal fluid (pH 6.8) for 4 hours, the simultaneous release rate of GABA and vitamin D is ≥90%, achieving precise intestinal delivery and making it suitable for industrial production.

The invention discloses a composite particle with a prebiotic function and colon-targeted co-delivery performance as well as a preparation method and application thereof, and belongs to the technical field of functional foods and intestinal micro-ecological regulators. According to the composite particle, the curcumin and the resveratrol are encapsulated by the peanut protein isolate to form a nano core, the outer layer of the nano core is a composite shell layer composed of the carboxymethyl konjac glucomannan and the prebiotics, a stable core-shell structure is formed, and the composite particle is small in particle size, good in dispersity and stability and good in stability. The stability of a protein-based delivery system in a gastrointestinal tract environment can be obviously improved; the release rate of the composite particles in simulated gastric juice and intestinal juice is low, and the composite particles can be specifically degraded and release active ingredients in simulated colon fluid containing beta-mannase, so that colon-targeted co-delivery can be realized. The composite particle disclosed by the invention is simple in preparation process and stable in function, can be applied to the fields of functional foods, health foods, formula foods for special medical purposes and the like, realizes dual purposes of active component delivery and intestinal microenvironment regulation, and has a wide application prospect.

This invention discloses a strain of Bifidobacterium animalis subspecies TRT-2A with allergy-relieving effects and its extracellular vesicle applications. The strain TRT-2A is deposited at the China Center for Type Culture Collection (CCTCC) on November 21, 2025, with accession number CCTCC NO:M 20252645. This strain is highly acid-resistant and exhibits good tolerance to artificial gastric and intestinal fluids. It effectively inhibits bacteria, particularly Streptococcus pyogenes, Streptococcus agalactiae, and / or Escherichia coli. Experimental results show that this strain can alleviate hormone-dependent dermatitis and effectively improve dermatitis symptoms such as erythema and desquamation. Furthermore, extracellular vesicles prepared using TRT-2A can effectively improve skin elasticity and reduce wrinkles. Therefore, the Bifidobacterium animalis subspecies TRT-2A of this invention has multiple functions and is worthy of further promotion and application.

The invention relates to a colon-targeted micro-ecological regulation composition. The colon-targeted micro-ecological regulation composition is prepared by compounding the following functional components in percentage by weight: 5-95% of a component A, 1-15% of a component B and 4-94% of a component C, the component A is resistant starch, the polymerization degree DP is greater than or equal to 15, and the crystallinity is greater than or equal to 35%; the component B is probiotics and is embedded through a complex coacervation method or an extrusion-gel method, the embedding rate is larger than or equal to 75%, and the particle size is 200-800 microns; the survival rate is greater than or equal to 60% after treatment in simulated gastric juice for 2 hours, and the survival rate is greater than or equal to 50% after treatment in simulated intestinal juice for 4 hours; the component C comprises functional nutritional auxiliary materials, the functional nutritional auxiliary materials comprise prebiotics and a medicinal and edible composition, and the prebiotics comprise rapid fermentation type prebiotics, medium-speed fermentation type prebiotics, slow fermentation type prebiotics and a non-fermentation type water-holding expansion component. By constructing a carbon source slow release-flora orientation-metabolism regulation ternary interaction collaborative network, accurate regulation and multi-target metabolism intervention of the whole digestive tract are realized.

The application discloses a pH response core-shell structure encapsulated insulin nanomicelle and a preparation method thereof. The encapsulated insulin mass accounts for 91% of the total mass of the insulin dissolved in an acidic aqueous solution, and the encapsulated insulin mass accounts for 13% of the mass of the encapsulated insulin nanomicelle. The average particle size of the micelle is 190 nm, and the Zeta potential is -19 mV. The nanomicelle is stable, the encapsulation efficiency and the drug loading capacity of the encapsulated insulin are 91% and 13% respectively, the cumulative release of the insulin mass percentage in a simulated human gastric juice environment with pH=1.2 for 2 h, 4 h and 10 h is 12%, 14% and 20% respectively, and the release of the insulin mass percentage in a simulated human intestinal juice environment with pH=7.4 for 2 h and 10 h is 55% and 77% respectively. Compared with the pH response block located in the core of the encapsulated insulin nanomicelle, the pH response block located in the shell of the encapsulated insulin nanomicelle has high stability in the simulated human gastric juice and has a slow-release behavior in the simulated human intestinal juice, and is more suitable for the bioavailability of the oral insulin of the human body.

The invention provides bacillus licheniformis capable of producing amylase, protease and cellulase and application of the bacillus licheniformis. The bacillus licheniformis is bacillus licheniformis FJAT-27214 and is preserved in the China General Microbiological Culture Collection Center on August 6, 2025, the preservation address is No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing, and the preservation number is CGMCC No. 35536. The bacillus licheniformis disclosed by the invention can be used for simultaneously producing amylase, protease and cellulase at high yield; the bacillus subtilis has antibacterial activity to escherichia coli and has certain tolerance to artificial gastric juice, artificial intestinal juice and cholate, the survival rate in the artificial gastric juice is 58.11%, the survival rate in the artificial intestinal juice is 82.58%, and the survival rate in the cholate is 28.03%. When the strain fermentation liquor is used for pomace micro-storage, the content of crude protein and total sugar of pomace can be remarkably increased, meanwhile, the content of neutral detergent fiber and ammoniacal nitrogen is remarkably reduced, and an effective strain resource is provided for pomace micro-storage fermented feed.

The utility model discloses a balloon plugging catheter structure for colorectal surgery, which belongs to the technical field of catheter structure buckles and comprises a main catheter, the top end of the main catheter is connected with a positioning disc, the top end of the positioning disc is connected with a drainage component, the main catheter comprises a main tube, one end of the main tube is connected with a first balloon, and the other end of the main tube is connected with a second balloon. The other end of the main tube is connected with a second balloon, the bottom end of the second balloon is connected with a drainage tube, open holes are formed in the periphery of the drainage tube, the outer wall of one side of the drainage tube is connected with an auxiliary tube, and a folding opening is formed in the outer wall of one side of the auxiliary tube. The main tube part of the catheter structure is communicated with the corresponding saccules through each group of cavity tubes and can be matched with expansion of the two groups of saccules, double-end blocking is formed during placement and fixation, the sealing stability of the intestinal fistula part is improved, intestinal juice is prevented from overflowing, a subsequent secondary retraction operation is not needed, and the main tube part can be matched with connection of a traction rope to adjust the bending degree of a drainage tube; the intestinal inner wall is prevented from being attached during drainage, and drainage stability is kept.

This invention discloses a strain of *Bacillus parabrachium* ABX1 and its applications, belonging to the field of beneficial microbial technology. The *Bacillus parabrachium* ABX1 provided by this invention is a Gram-positive bacterium isolated from the intestinal fluid of *Bombyx mori*. On CMC-Na solid medium, the ratio of the diameter of the hydrolysis zone to the colony diameter can reach 11. Enzyme activity identification results show that the filter paper enzyme activity of *Bacillus parabrachium* ABX1 is as high as 109.79 U·mL. ‑1 The exo-β-glucanase activity was 107.59 U·mL. ‑1 The cellulase activity reached 107.37 U·mL ‑1 It exhibits excellent cellulose and / or crystalline cellulose degradation capabilities; it is easy to use and has a wide range of enzyme production conditions, showing excellent enzyme activity at pH 5–10 and 25–50℃; the enzyme production time is short, with high enzyme yield achieved in just 12 hours, and there is no significant adverse effect on enzyme yield with prolonged reaction time; it is highly safe to use and has great application prospects in areas such as oak garden waste branch treatment, improvement of oak silkworm digestibility, industrial degradation of cellulose, and improvement of soil fertility.

This invention discloses a strain of *Lactobacillus warfarinii* Z40 and its applications. The taxonomic name of *Lactobacillus warfarinii* Z40 is... Limosilactobacillus walteri Z40, deposited on May 18, 2026 at the China Center for Type Culture Collection (CCTCC), accession number CCTCC NO: M 20261007. This invention isolates a strain of *Lactobacillus warfarinii* Z40 from the intestines of healthy children. It exhibits certain resistance to gastric acid and high bile salts in intestinal fluid, and is non-hemolytic. Mouse model experiments have verified that it can effectively reduce the body weight of obese mice, decrease visceral fat accumulation, lower blood lipid levels, improve abnormal glucose metabolism in mice, and significantly reduce intestinal permeability, thereby improving abnormal phenotypes in mice in multiple ways. It can be applied to products related to weight loss, lowering blood lipids, lowering blood sugar, and improving intestinal barrier function.

The application discloses an automatic pressure regulating negative pressure suction device with automatic humidification function, which comprises a tracheal catheter, a closed sputum suction tube connected to the tail end of the tracheal catheter, a humidification tube connected to a humidification tube port on the closed sputum suction tube, an infusion device connected to the upper end of the humidification tube, sterile humidification liquid connected to the infusion device, a quantitative injection device additionally arranged outside a Murphy dropper of the infusion device, and a pressure pump provided with a volume sensor and a closed air bag wrapping the Murphy dropper, wherein the tail end of the closed sputum suction tube is connected to a disposable negative pressure suction liquid storage bottle through a suction device leather strap, and another connecting port of the negative pressure suction bottle is connected to a negative pressure suction pressure regulating table. According to the application, pressure modules are selected according to different suction liquids (sputum, bile, intestinal fluid, cerebrospinal fluid, etc.), a standard negative pressure value range is adjusted by one key, and the application is convenient to use. In addition, the automatic humidification can be performed on thick sputum for the sputum suction operation, the sputum is made to be thin, and the suction is facilitated.

The present application relates to the technical field of microorganisms, and particularly relates to a bifidobacterium BGLP1 capable of regulating sugar digestion and high GLP-1 production and application thereof. Bifidobacterium bifidum The bifidobacterium BGLP1 (CGMCC No. 35718) has the abilities of inhibiting alpha-glucosidase and alpha-amylase, stimulating STC-1 cells to secrete GLP-1 and activating the intestinal glucose-lowering pathway, significantly inhibiting pancreatic lipase activity and effectively reducing dietary fat absorption, converting excess sucrose into extracellular polysaccharides to increase the probiotic function, promoting the conversion of white fat into brown fat, and activating macrophages and improving the immune function of the body. In addition, the bifidobacterium BGLP1 has strong intestinal colonization ability, has good tolerance in artificial gastric juice and artificial intestinal juice, and can successfully reach the human intestinal tract.

The application relates to the embedding technical field, and particularly discloses a double emulsion gel bead embedding beta-carotene and probiotics and a preparation method thereof. The double emulsion gel bead comprises a composite layer, an oil phase and an inner water phase from outside to inside. The composite layer comprises an outer water phase and calcium alginate which are fused with each other. The outer water phase comprises a product after carrageenan and sodium caseinate are subjected to a Maillard reaction. The oil phase comprises beta-carotene, vegetable oil and a food emulsifier. The inner water phase comprises probiotics. In the gel bead, the beta-carotene and the probiotics are simultaneously embedded in the double emulsion gel bead, the calcium alginate hydrogel shell starts to decompose when entering the intestinal tract, then the double-layer emulsion is slowly decomposed after being subjected to chemical digestion of pancreatic juice, bile and small intestinal juice and mechanical digestion of the small intestine in the small intestine, and the beta-carotene and the probiotics are gradually released, the beta-carotene is converted into vitamin A in the intestinal tract and is absorbed, and the probiotics are delivered to the colon to play a probiotic effect.

The application discloses a liposome curcumin composition for assisting in controlling blood sugar and regulating kidney and application thereof, and belongs to the technical field of food and health food. The composition adopts a modular formula design and comprises a basic active component and an optional kidney protection component. The particle size of the liposome curcumin is accurately controlled to be 60-80 nm, the encapsulation rate is greater than or equal to 80%, the ethanol residue is less than or equal to 0.5 ‰, the gastric juice 2h release rate is less than 33%, and the intestinal juice 2h release rate is greater than 80%. By differentially adjusting the component amount, two scenes of simple blood sugar reduction and blood sugar reduction and kidney protection can be adapted, and bidirectional synergy of stable blood sugar regulation and kidney target maintenance can be realized. The application also provides application of the composition in oral liquid, solid beverage, soft capsule and tablet. It is verified through experiments that the bioavailability of the composition is more than 12 times higher than that of conventional curcumin preparation, the postprandial blood sugar peak value is reduced by 25%-30%, the urinary protein excretion rate is reduced by 18%-22%, the safety and compliance are excellent, and the composition is suitable for industrial production.

The invention relates to the technical field related to microcapsules, in particular to a preparation method of a wheat alpha-glucosidase inhibitory peptide microcapsule, which comprises the following steps: by taking wheat vital gluten as a raw material, carrying out enzymolysis by alkaline protease to obtain alpha-glucosidase inhibitory peptide, and then carrying out enzymolysis by adopting a sodium alginate-chitosan composite wall material system to obtain the wheat alpha-glucosidase inhibitory peptide microcapsule. By optimizing key parameters such as the core-wall ratio of 1: 2.632, the calcium chloride concentration of 2.48% and the curing time of 31.83 min, the double-layer microcapsule with the pH response characteristic is prepared by an ionic gel method. The embedding rate of the prepared microcapsule reaches 78.26%, the 2-hour release rate in simulated gastric juice (pH 2.0) is smaller than or equal to 21.38%, the 4-hour accumulative release rate in simulated intestinal juice is larger than or equal to 84.98%, and stomach protection and intestinal targeted release of the active peptide are achieved; meanwhile, the peptide loss rate of the product under the storage condition of 4 DEG C is less than or equal to 11.13%, the loss rate in the environment with the pH value of 2.0 is only 12.72%, and the stability of the active peptide is remarkably improved. The obtained product can effectively protect the activity of the alpha-glucosidase inhibitory peptide and improve the bioavailability of the alpha-glucosidase inhibitory peptide, and a new scheme is provided for developing functional hypoglycemic food.

The invention relates to the field of hair growth nutrients, and discloses a nutrient composition for promoting hair growth and a preparation method thereof, the composition comprises a basic hair growth nutrient group and an absorption-promoting synergistic group; the basic hair growth nutrition group comprises the following components in parts by weight: 0.3-0.8 part of ferrous lactate, 2-5 parts of zinc gluconate, 5-8 parts of magnesium stearate, 3-8 parts of a coating material and 17-25 parts of milk mineral salt; the absorption-promoting synergistic group comprises the following components in parts by weight: 0.2-1.5 parts of a black pepper extract, 2-10 parts of lecithin and 2-8 parts of casein phosphopeptides, the black pepper extract and the lecithin are firstly released, an intestinal epithelium channel is opened by utilizing a biological penetration promoting effect, and a pre-permeation state is established; the subsequently released CPP is complexed with divalent metal ions in intestinal juice to prevent precipitation, so that the CPP is synchronously and rapidly absorbed through a pre-opened channel, and the problems of competitive antagonism and difficult absorption of high-dose minerals are effectively solved.

The preparation method comprises the following steps: (1) compounding hermetia illucens larvae, whole tenebrio molitor and euphausia superba according to a mass ratio of (3-5): (2-4): 1, carrying out enzymolysis, and reacting with a yeast cell wall extract to form a glycopeptide compound; (2) coating the glycopeptide compound with a mannan oligosaccharide and chitosan solution to form microcapsules, and controlling the release rate of the microcapsules in simulated gastric juice to be lower than 30% and the release rate of the microcapsules in simulated intestinal juice to be higher than 80%; (3) co-fermenting the microcapsules, clostridium butyricum and pediococcus acidilactici, and adsorbing fermentation liquor on the porous starch; (4) performing dry mixing on the functional compound, the fermentation compound and the base material, and performing low-temperature puffing; and (5) sequentially spraying a vitamin D3 grease layer, a pectin-whey protein protective layer and a solution containing TGF-beta2 on the surfaces of the particles. Through cooperation of multiple processes, the immune function and intestinal health of pets are remarkably improved, and the product is good in stability and palatability.

A probiotic microsphere with in-situ proliferation, its preparation method and application. The microsphere is prepared by a two-step Pickering double emulsion method, encapsulating probiotics and panax notoginseng saponins, and then mixed with sodium alginate and cross-linked by calcium ions. The structure significantly improves the survival rate of probiotics in simulated gastric juice, intestinal juice, heat treatment and antibiotic environment, and maintains high viable cell count during long-term storage. Co-encapsulated PNS and double emulsion stabilizer natural polysaccharide-protein nanocomposite can promote the proliferation of probiotics in-situ, increase their activity. In addition, the microsphere can effectively promote the colonization and proliferation of probiotics in the intestinal tract, enhance the oral bioavailability of bioactive ingredients, and is suitable for functional food, feed, biological medicine field, especially as 3D printing special medical food for dysphagia population and prevention and treatment of intestinal inflammatory diseases.

This invention discloses a method for evaluating the bioavailability of soybean oil based on an in vitro digestion / cell co-culture model. Soybean oil is emulsified using WPI emulsifier and then digested sequentially through simulated gastric and intestinal fluids to obtain the gastric digestion products of soybean oil. Fatty acids are extracted from the intestinal digestion products of soybean oil, dissolved in dimethyl sulfoxide, and linked to fatty acid-free bovine serum albumin to obtain in vitro digestion products of soybean oil that can be absorbed by the intestines. These are then added to a cell co-culture model for cell incubation and transport. HepG2 cells from the cell co-culture model are collected, and Oil Red O staining and total triglyceride content are measured to obtain lipid deposition, thereby evaluating the bioavailability of soybean oil. The in vitro digestion / cell co-culture model of this invention is specifically designed for soybean oil digestion. This method objectively and scientifically evaluates the bioavailability of soybean oil at different metabolic stages, providing a standard basis for the scientific and healthy consumption of soybean oil and possessing significant practical value.

The present application relates to the technical field of medical devices, and discloses an intestinal fluid intermittent return method and system based on pressure self-adaptation, wherein multi-modal sensor network is used to collect patient situation state, physiological rhythm and intestinal pressure data to obtain multi-dimensional monitoring data flow; time series signal processing technology is used to extract the corresponding phases of each data and calculate synchronization metrics; a synchronous state classification model is used for collaborative state classification; based on the classification result, a return decision instruction is generated to control the return device and adjust the return parameters according to the intestinal pressure; in addition, the present application also uses an incremental learning algorithm to adjust the model threshold and decision parameters based on individualized data sets, which can accurately control the return timing and parameters, and improve the return effect and safety of intestinal fluid.

The invention discloses a bifidobacterium animalis subsp. Lactis BT-G9 with a growth promoting function and application of the bifidobacterium animalis subsp. Lactis BT-G9, the bifidobacterium animalis subsp. Lactis BT-G9 is preserved in China Center for Type Culture Collection, the preservation date is November 20, 2025, and the preservation number is CCTCC NO: M 20252626. The brand new bifidobacterium animalis subsp. Lactis BT-G9 provided by the invention has good tolerance to gastric juice and intestinal juice, is suitable for survival in gastrointestinal tracts, can effectively inhibit bacteria, and particularly can effectively inhibit campylobacter kirscheri, streptococcus agalactiae and / or propionibacterium acnes. Experimental results show that the strain can promote animal growth and development and improve the autism, especially when the animal bifidobacterium subsp. Lactis BT-G9 and the lactobacillus acidophilus BT-C15 are combined for use, the animal bifidobacterium subsp. Lactis BT-G9 and the lactobacillus acidophilus BT-C15 have a synergistic effect, and the improvement effect on the autism can be remarkably improved. In addition, the extracellular vesicles prepared from the strain can effectively repair the skin barrier function.

The invention discloses a sampling capsule and a sampling system thereof.The sampling capsule comprises a shell, a first permanent magnet, a second permanent magnet, a flexible part and a soluble supporting frame, and when an enteric-coated ring is not dissolved, the same poles of the first permanent magnet and the second permanent magnet are opposite to each other, so that the mutual repulsive magnetic action is formed between the first permanent magnet and the second permanent magnet; the enteric-coated ring is used for dissolving to form a liquid inlet, and intestinal juice enters the sampling capsule through the liquid inlet; the first end cover and the second end cover are gradually separated, under the mutual repulsive magnetic force effect between the first permanent magnet and the second permanent magnet, the telescopic section is pulled, stretched and lengthened, the distance between the first end cover and the second end cover is increased, the soluble supporting frame is at least partially dissolved in intestinal juice, and the second permanent magnet is used for rotating under the effect of an external magnetic field. The first permanent magnet and the second permanent magnet attract each other, the second permanent magnet pushes the second part to be close to the first permanent magnet, and the edges of the first end cover and the second end cover are buckled so as to seal and store intestinal juice entering the sampling capsule.

The application discloses a process and system for preparing nutritional feed by using oil refining waste residue, and the process comprises the following steps: guiding impurities to embed into the growth edge of a crystal lattice by slowly reducing the temperature in the initial stage of a segmented temperature reduction program, and promoting the surface to form a crystalline shell layer with certain mechanical strength and structural defects; after entering the intestinal environment of crustacean aquatic products, the shell layer is eroded by intestinal fluid and the overall structure is fractured along the defect area, and the solid oil gel network inside the shell layer exerts a structural binding force on the shell layer in the early stage to maintain the prestressed state of the defect area, and the physical impact force released at the moment of shell layer fracture is completely transmitted to the network inside, so that the physical impact force generated by the collapse of the shell directly pulverizes the solid oil gel network inside, and the solid oil gel network is rapidly disintegrated and dispersed into free oil in a high dispersion state in the intestinal tract, so that the complete release and efficient absorption of lipid nutrition are realized.

Two-layer drug structure (1) comprising the following: an inner core (11) which is spherical in shape, wherein the inner core (11) contains a pharmaceutically active component; an enveloping polymer layer (12) having a thickness wherein the enveloping polymer layer (12) envelops the outer surface of the inner core (11), wherein the enveloping polymer layer (12) shrinks inwards in a gastric acid environment and swells outwards in an intestinal environment; and a multitude of hydrophilic pore-forming particles (13) embedded in the enclosing polymer layer (12), wherein the hydrophilic pore-forming particles (13) are exposed to the outside when the enclosing polymer layer (12) swells and dissolve in the intestinal fluid to form channels.

The invention provides a roxburgh rose source intelligent delivery system and a preparation method and application thereof. The system is formed by self-assembling roxburgh rose endogenous components through physical field programming induction, and simultaneously meets the following requirements: (1) the molar ratio of Cu < 2 + > to Mn < 2 + > is (1: 5.5)-(1: 6.5), and the molar ratio of Cu < 2 + > to Sr < 2 + > is (1: 0.45)-(1: 0.51); (2) the Zeta potential is-5 mV to + 5 mV, and the conductivity is lt; 10 S / cm; (3) a release rate lt in simulated gastric juice; the release rate gt in simulated intestinal juice within 2 hours is 10%; 80%; and (4) in terms of solids, single administration MTD is greater than or equal to 5.0 g / kg. The system has nearly neutral Zeta potential and extremely low conductivity, keeps stable in long-term storage, can synergistically reduce serum uric acid, transaminase and blood sugar, and has a kidney protection effect while efficiently reducing uric acid. The invention further provides a green preparation method of the system and multi-field application of the system.

The invention discloses an intestinal juice feedback control method and system based on physiological parameter self-adaptive adjustment, and relates to the technical field of intestinal juice feedback control. The intestinal juice feedback control method based on physiological parameter self-adaptive adjustment comprises the following steps of intestinal juice filtration and absorption, negative pressure control optimization, intestinal juice feedback and intestinal juice feedback optimization. According to the method, evaluation for measuring the negative pressure control stability is carried out, whether the requirement for negative pressure control optimization exists or not is judged, if yes, negative pressure control optimization is carried out based on the judgment result of the current filtering working condition of the intestinal juice feedback device, the air bag pressure is established after negative pressure control optimization, and if not, the air bag pressure is directly established; the intestinal tract pressure is monitored to identify the intestinal tract peristalsis wave, the evaluation for measuring the intestinal tract liquid feedback timeliness is carried out after the intestinal tract liquid feedback, and finally, whether the feedback timeliness optimization is carried out or not is judged based on the timely evaluation result, so that the intestinal tract liquid feedback control effectiveness is improved, and the problem that the intestinal tract liquid feedback control effectiveness is poor in the prior art is solved.